- Home
- RIGL vs CPS Comparison
RIGL vs CPS Comparison
Compare RIGL & CPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | CPS |
|---|---|---|
| Founded | 1996 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 544.9M |
| IPO Year | 2000 | 2005 |
Fundamental Metrics
Financial Performance| Metric | RIGL | CPS |
|---|---|---|
| Price | $40.45 | $28.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $45.67 | ★ $51.88 |
| AVG Volume (30 Days) | ★ 386.8K | 139.9K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | 94.87 |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | N/A | $4.42 |
| Revenue Next Year | $12.75 | $6.36 |
| P/E Ratio | $93.09 | ★ N/A |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $18.70 | $22.32 |
| 52 Week High | $52.24 | $47.98 |
Technical Indicators
Market Signals| Indicator | RIGL | CPS |
|---|---|---|
| Relative Strength Index (RSI) | 64.43 | 53.40 |
| Support Level | $40.05 | $28.00 |
| Resistance Level | $44.85 | $31.90 |
| Average True Range (ATR) | 1.82 | 1.45 |
| MACD | -0.04 | 0.14 |
| Stochastic Oscillator | 58.00 | 65.22 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About CPS Cooper-Standard Holdings Inc.
Cooper-Standard Holdings Inc is engaged in the manufacture of sealing and fluid handling systems (consisting of fuel and brake delivery systems and fluid transfer systems). Its products are designed for passenger vehicles and light trucks that are manufactured by automotive original equipment manufacturers (OEMs) and replacement markets. It has two reportable segments: Sealing Systems and Fluid Handling Systems. The group's geographic regions are North America, Europe, Asia Pacific, and South America.